Last updated: April 11, 2026
MENQUADFI (brolucizumab-dbll) is a biologic drug developed for intravitreal use, primarily targeting neovascular age-related macular degeneration (nAMD). As a member of the anti-vascular endothelial growth factor (VEGF) class, MENQUADFI competes with established therapies such as aflibercept, ranibizumab, and bevacizumab. Its market presence is influenced by regulatory approvals, clinical efficacy, safety profile, and competitive pressure.
Regulatory Status and Adoption
MENQUADFI received FDA approval in October 2022. Regulatory agencies in Europe and Japan are reviewing the drug, with approval expected in Q4 2023 and Q1 2024, respectively [1].
Initial adoption rates are moderate, driven by clinician familiarity with anti-VEGF therapies and the drug’s less frequent dosing schedule (every 12 weeks after the initial loading phase). Key factors influencing uptake include:
- Demonstrated non-inferiority to aflibercept in clinical trials.
- Reduced treatment burden due to longer dosing intervals.
- Limited long-term safety data compared to established therapies.
Market Size and Forecast
The global market for anti-VEGF drugs treating nAMD was valued at approximately USD 8.2 billion in 2022. The market is projected to grow at a compound annual growth rate (CAGR) of 7% from 2023 to 2030 [2].
Market Segmentation:
| Segment |
2022 Market Share |
Growth Drivers |
| Aflibercept |
45% |
Established efficacy, broad approval |
| Ranibizumab |
30% |
Widely used, proven track record |
| Bevacizumab |
15% |
Cost-effective, off-label use |
| Other (including MENQUADFI) |
10% |
Innovation, dosing convenience |
MENQUADFI, as a new entrant, holds an initial share estimated at 2-3% in 2023, with potential to reach double digits by 2028 if clinical data and safety profiles are validated.
Competitive Landscape
| Drug |
Approval Year |
Dosing Frequency |
Key Advantages |
Challenges |
| Aflibercept |
2011 |
Every 8 weeks |
Proven efficacy, widespread adoption |
Injection frequency, side effects |
| Ranibizumab |
2006 |
Monthly or as needed |
Extensive clinical data |
Frequent injections, cost |
| Bevacizumab |
2004 |
Variable, off-label |
Cost advantage |
Immunogenicity concerns, safety profile |
| MENQUADFI |
2022 |
Every 12 weeks |
Reduced injection frequency, comparable efficacy |
Long-term safety, cost |
Competitive differentiation hinges on MENQUADFI's extended dosing interval, which can reduce treatment burden, potentially improving patient adherence.
Pricing and Reimbursement
Pricing strategies for biologics like MENQUADFI are critical. The drug's list price in the U.S. has been set at approximately USD 2,500 per dose, aligning with aflibercept but lower than ranibizumab. Reimbursement negotiations are ongoing, with payers assessing value based on reduced injection frequency and clinical outcomes.
In Europe, reimbursement frameworks differ; countries such as Germany and the UK are evaluating cost-effectiveness, considering the potential for long-term savings from fewer clinic visits.
Key Financials and Potential Revenue
Assuming:
- 1 million patients with nAMD globally.
- 50% treatment penetration over five years.
- MENQUADFI captures 10% of treated patients within three years.
Projected revenue could reach USD 600 million annually by 2026:
| Assumption |
Value |
| Market penetration (2026) |
10% of 500,000 treated patients |
| Average annual treatment cost per patient |
USD 10,000 |
| Estimated revenue |
USD 600 million |
This projection assumes competitive pricing and steady adoption, with escalations tied to clinical validation and payer acceptance.
Risks and Opportunities
Risks:
- Safety concerns related to intraocular inflammation, as observed in post-marketing surveillance of similar biologics.
- Competition from biosimilars and new anti-VEGF agents.
- Market retention challenges if long-term efficacy data reveal limitations.
Opportunities:
- Expanding indications, including diabetic macular edema.
- Combination therapies with other ocular biologics.
- Geographical expansion into emerging markets with increasing ophthalmology access.
Key Takeaways
- MENQUADFI entered the market in 2022, with initial moderate adoption, targeting an established but competitive nAMD segment.
- Its long dosing interval offers a differentiation that can increase patient convenience and treatment adherence.
- The global anti-VEGF market is growing, driven by aging populations and increasing diagnosis rates.
- Revenue potential hinges on clinical validation, payer policies, and market penetration strategies.
- Long-term safety profiles and competitive innovations remain critical to sustained success.
FAQs
1. How does MENQUADFI compare clinically to other anti-VEGF therapies?
It has shown non-inferiority to aflibercept in phase 3 trials, with comparable efficacy and a longer dosing interval (12 weeks versus 8 weeks).
2. What are the main safety concerns associated with MENQUADFI?
Possible intraocular inflammation and retinal vasculitis have been reported in post-marketing data; ongoing safety monitoring is essential.
3. When is MENQUADFI expected to gain broader approval globally?
Approval is anticipated in Europe and Japan during late 2023 to early 2024, contingent on regulatory review outcomes.
4. What factors influence the drug’s market uptake?
Clinician familiarity, safety data, pricing, reimbursement policies, and patient adherence rates.
5. Could biosimilars impact MENQUADFI’s market share long-term?
Yes, biosimilar development could reduce prices and challenge market share if they demonstrate comparable efficacy and safety.
References
[1] FDA. (2022). Approval announcement for MENQUADFI. Retrieved from https://www.fda.gov
[2] MarketWatch. (2023). Anti-VEGF drugs market report. Retrieved from https://www.marketwatch.com
